A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Sep 20, 2021

Keywords

ClinConnect Summary

The IM@HOME clinical trial is studying a program that offers virtual mind-body therapies to help people with certain types of cancer, including head and neck cancer, ovarian cancer, and melanoma, among others. The goal is to see if this program can improve how patients feel and cope while undergoing treatments like chemotherapy, immunotherapy, or radiation. The trial is currently looking for participants who are 18 years or older, actively receiving cancer treatment, and experiencing a certain level of fatigue.

If you or a loved one is eligible, joining the trial means you’ll have the chance to access supportive therapies designed to enhance your treatment experience. Participants will be randomly assigned to either receive the IM@HOME program or standard care. This study is open to English-speaking patients who have a good life expectancy and can engage with the study assessments. It’s important to know that those with cognitive impairments or who are already participating in similar trials may not be eligible. Overall, this trial aims to provide valuable insights into how integrative medicine can benefit patients during their cancer treatment journey.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years or older
• • Karnofsky score 60 or greater
• • Life expectancy greater than six months
• • English speaking
• • Additional Inclusion Criteria for Head and Neck, Thoracic, Gynecologic, Melanoma and Breast Baskets
• • Patients with a diagnosis of head and neck tumors, thoracic tumors, gynecological tumors, melanoma, breast cancer, or gynecologic cancer
• • Actively receiving systemic oncological treatment or radiotherapy, or within 4 weeks of radiotherapy completion or primary cytoreductive surgery
• • Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)
• • Additional Inclusion Criteria for First Remission Gynecologic Cancer Basket
• • Patients with a diagnosis or clinical suspicion of gynecologic malignancy who have completed definitive first line treatment (maintenance hormonal or targeted therapies are allowed)
• Additional Inclusion Criteria for the Advanced Cancer Basket:
• • Patients with a diagnosis of Stage III or IV lung cancer; any stage pancreatic cancer, unresectable cholangiocarcinoma, unresectable liver cancer, unresectable ampullary or peri-ampullary cancer, or other stage IV gastrointestinal cancer; stage III or IV ovarian or fallopian tube cancers or other stage IV gynecologic cancer; stage IV breast cancer; stage III testicular cancer or any stage IV genitourinary cancer; stage IV sarcoma; stage IV melanoma; stage IV endocrine cancer; lymphoma, myeloma, or Leukemia
• • Actively receiving oncological treatment, radiotherapy or active surveillance
• Additional Inclusion Criteria for the Cancer Survivor Basket:
• • Completed active cancer treatment (e.g., surgery, radiation, chemotherapy) (maintenance hormonal or targeted therapies are allowed).
• • Worst fatigue over the last 7 days rated 4 or greater on (0-10 scale)
• Exclusion Criteria:
• • Cognitive impairment that would preclude response to study assessments or require the use of Legally Authorized Representatives
• • Unwilling to accept random assignment
• • Concurrently enroll onto ongoing competing trials of integrative medicine interventions with symptom/toxicity as primary outcome. Note, however, patient will be allowed to enroll on other therapeutic protocols